Company Presentation

4TEEN4 Pharmaceuticals is developing Procizumab, an inhibitor of DPP3 pathway. A breakthrough, first in class asset with pre-clinical proof of concept to restore cardiac function and prevent death due to Cardiogenic Shock. 4TEEN4 Pharmaceuticals pioneers precision medicine to restore cardiac and vascular function and to prevent fatalities in critical acute cardiovascular complications with limited or no effective therapies available.